Overview

This trial is active, not recruiting.

Condition lung cancer
Treatments carboplatin, paclitaxel, conventional surgery, radiation therapy
Phase phase 2
Sponsor Fox Chase Cancer Center
Start date July 2002
End date December 2006
Trial size 57 participants
Trial identifier NCT00043108, CDR0000256334, FCCC-02014, NCI-G02-2097, P30CA006927

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving combination chemotherapy with radiation therapy before and after surgery may shrink the tumor so it can be removed during surgery and may kill any remaining tumor cells following surgery.

PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and carboplatin with radiation therapy and surgery in treating patients who have newly diagnosed locally advanced non-small cell lung cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Masking open label
Primary purpose treatment

Primary Outcomes

Measure
Maximum tolerated dose
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 120 years old.

DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed, newly diagnosed, unilateral primary non-small cell lung cancer (NSCLC) - Must have involvement of the superior sulcus, chest wall, or mediastinum - Must have at least 1 of the following: - Locally advanced Pancoast tumors with no documented mediastinal or supraclavicular nodal involvement (T3-T4, N0-1) - Resectable chest wall disease (T3, N0-1) - Marginally resectable T4, N0-1, or NX central NSCLC - N2 patients who are potentially resectable after induction chemoradiotherapy - No evidence of extrathoracic spread to liver, adrenals, brain, or bone - No evidence of supraclavicular nodes, malignant pleural or pericardial effusions, or distant metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 70-100% Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 2,000/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin no greater than 1.5 mg/dL - SGOT no greater than 3 times upper limit of normal Renal - Creatinine no greater than 2.0 mg/dL Cardiovascular - No superior vena cava syndrome - No myocardial infarction within the past 6 months - No active uncontrolled congestive heart failure - No active uncontrolled arrhythmia within the past 6 months Pulmonary - FEV1 at least 800 mL Other - No other active invasive malignancy requiring therapy within the past 2 years - No ongoing need for adjuvant therapy - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 3 months after study entry PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - No prior pelvic or thoracic radiotherapy Surgery - See Disease Characteristics Other - Concurrent beta blockers, digitalis derivatives, or channel-blocking agents allowed provided cardiac conditions are stable

Additional Information

Official title Trimodality Protocol for the Treatment of Locally Advanced, Potentially Resectable Non-Small Cell Lung Cancer Targeting
Principal investigator Aruna J. Turaka, MD
Description OBJECTIVES: - Determine the complete resection rate and toxic death rate of patients with locally advanced non-small cell lung cancer treated with paclitaxel, carboplatin, and radiotherapy followed by surgical resection and adjuvant paclitaxel and carboplatin. - Determine the survival, event-free survival, and incidence of pathologic complete remission of patients treated with this regimen. - Determine the protocol completion rate (CR) of patients treated with this regimen. - Determine the feasibility and toxicity of this regimen in these patients. - Determine the pathologic response rate/downstaging, pathologic near CR rate, freedom from distant metastasis rate, and freedom from local regional failure rate of patients treated with this regimen. OUTLINE: Patients receive induction therapy comprising radiotherapy 5 days a week for 5.5-6 weeks and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Within 1-3 weeks after completion of induction therapy, patients undergo restaging. Patients with resectable disease undergo surgical resection within 4-8 weeks after induction therapy. Patients with unresectable disease undergo additional radiotherapy 5 days a week for 3 weeks and receive paclitaxel and carboplatin as in induction therapy on days 1, 8, and 15. Within 4-12 weeks after surgery or additional chemoradiotherapy, patients receive adjuvant therapy comprising paclitaxel and carboplatin as in induction therapy on day 1. Adjuvant treatment repeats every 4 weeks for 3 courses. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: Approximately 57 patients will be accrued for this study within 4 years.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Fox Chase Cancer Center.